Expired CME Article

Management of Status Epilepticus in Infants and Children Prior to Pediatric ICU Admission: Deviations from the Current Guidelines

Authors: Joseph D. Tobias, MD, John W. Berkenbosch, MD

Abstract

Objectives: Despite the availability of guidelines for the treatment of status epilepticus (SE), there may be variability in the initial stabilization, evaluation, and pharmacologic treatment of infants and children with SE. To improve the treatment of such patients, documentation of these problems is needed. The current study is a prospective observational evaluation of the care received by pediatric patients with SE before Pediatric Intensive Care Unit (PICU) admission.


Methods: Following admission to the PICU, the care received was reviewed from the available records and/or direct conversations with the healthcare providers.


Results: The study cohort included 100 consecutive patients with SE. Potential issues in care included lack of laboratory evaluation. The following laboratory parameters were not obtained during the initial evaluation: serum sodium (9% of patients), serum or ionized calcium (22%), and serum glucose (16%). When serum glucose was measured, results were not available for 20 minutes or more in 37% of the patients. Ninety-two patients were treated with anticonvulsant medication as they were having active seizure activity at the initial presentation. Primary drug therapy for SE did not include a benzodiazepine in 11% of the treated patients. When a benzodiazepine was administered, dosing was outside of suggested guidelines in 22.5% of patients. Respiratory compromise was more common in patients who received a benzodiazepine dose greater than suggested guidelines.


Conclusions: Education regarding the initial evaluation and treatment of SE should focus on the appropriate laboratory evaluation required, suggested drug therapy, and dosing guidelines.


Key Points


* In our cohort of patients with status epilepticus (SE), the following laboratory parameters were not obtained during initial evaluation: serum sodium (9% of patients), serum or ionized calcium (22%), and serum glucose (16%). When serum glucose was measured, the results were not available for 20 minutes or more in 37% of the patients.


* Primary drug therapy for SE did not include a benzodiazepine in 11% of the patients.


* Benzodiazepine dosing was outside of accepted guidelines in 22.5% of patients.


* Respiratory compromise was more likely in patients who received an initial benzodiazepine dose that was greater than suggested guidelines.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Lippik IE. Status epilepticus. Clin Ther 1985;7:272–278.
 
2. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46:1029–1035.
 
3. Chin RF, Neville BG, Scott RC. A systematic review of the epidemiology of status epilepticus. Eur J Neurol 2004;11:800–810.
 
4. Hirtz D, Ashwal S, Berg A, et al. Practice parameter: evaluating a first nonfebrile seizure in children: report of the quality standards subcommittee of the American Academy of Neurology, The Child Neurology Society, and The American Epilepsy Society. Neurology 2000;55:616–623.
 
5. American Academy of Pediatrics. Provisional Committee on Quality Improvement, Subcommittee on Febrile Seizures. Practice parameter: the neurodiagnostic evaluation of a child with a first simple febrile seizure. Pediatrics 1996;97:769–772.
 
6. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993;270:854–859.
 
7. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998;338:970–976.
 
8. Lowenstein DH. Treatment options for status epilepticus. Curr Opin Pharmacol 2005;5:334–339.
 
9. Hirtz D, Berg A, Bettis D, et al. Practice parameter: treatment of the child with a first unprovoked seizure. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2003;60:166–175.
 
10. Medolago-Albani L, Conforti A, Palladini G, et al. Ultrastructural changes in the central nervous system in experimental hypoglycemia. Acta Neurol 1983;5:174–179.
 
11. Blattner RJ. Central nervous system damage and hypoglycemia. J Pediatr 1968;72:904–906.
 
12. Riviello JJ Jr, Ashwal S, Hirtz D, et al. Practice parameters: Diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2006;67:1542–1550.
 
13. Haafiz A, Kissoon N. Status epilepticus: current concepts. Pediatr Emerg Care 1999;15:119–129.
 
14. Wolfe TR, Macfarlane TC. Intranasal midazolam therapy for pediatric status epilepticus. Am J Emerg Med 2006;24:343–346.
 
15. Galdames-Contreras D, Carrasco-Poblete E, Aguilera-Olivares L, et al. Intramuscular midazolam in the initial treatment of status epilepticus. Rev Neurol 2006;42:332–335.
 
16. Committee on Drugs. Drugs for pediatric emergencies. Pediatrics 1998;101:e13.